Announcement

Collapse
No announcement yet.

Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans

    The Journal of Infectious Diseases 2008;197:000?000? 2008 by the Infectious Diseases Society of America. All rights reserved.
    0022-1899/2008/19704-00XX$15.00
    DOI: 10.1086/526537

    BRIEF REPORT
    Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans

    Kenneth M. Zangwill,<sup>1</sup>
    John J. Treanor,<sup>2</sup>
    James D. Campbell,<sup>3</sup>
    Diana L. Noah,<sup>5</sup> and
    Jennifer Ryea<sup>4</sup>
    <sup>1</sup>University of California, Los Angeles (UCLA), Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor‐UCLA Medical Center, Los Angeles; <sup>2</sup>University of Rochester, Rochester, New York; <sup>3</sup>University of Maryland School of Medicine Center for Vaccine Development, Baltimore, and <sup>4</sup>Emmes Corporation, Rockville, Maryland; <sup>5</sup>Southern Research Institute, Birmingham, Alabama
    Received 21 June 2007; accepted 7 August 2007; electronically published 29 January 2008.
    • Potential conflicts of interest: none reported.
      Presented in part: Options for the Control of Influenza VI, Toronto, 17?23 June 2007.
      Financial support: National Institute of Allergy and Infectious Diseases, National Institutes of Health (contracts N01 AI 25460, AI 25461, AI 25463, and AI 30068 ); federal General Clinical Research Center (grants M01 RR00044, M01 RR165001, and M01‐RR00425).

    Reprints or correspondence: Dr. Kenneth Zangwill, Liu Research Building, Harbor‐UCLA Medical Center, 1124 W. Carson St., Torrance, California 90502 (kzangwill@labiomed.org).

    Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18?64 years of age (placebo and 7.5‐, 15‐, 45‐, or 90‐μg doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter. Microneutralization (MN) and hemagglutination‐inhibition geometric mean titers (GMTs) of antibody declined before the third dose. Twenty‐eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90‐, 45‐, 15‐, and 7.5‐μg‐dose groups had a MN GMT 1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (Trial registration: Clinical Trials.gov identifier NCT00240968.)



Working...
X